Vaxart Inc. (OTCQX: VXRT) reported Phase 1 clinical trial data showing its second-generation oral norovirus vaccine candidates produced stronger immune ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE